Special Purpose Acquisition Companies (SPACs), have seen a resurgence in popularity over the past 2 years, and it’s easy to see why.
DFIN has published their October U.S. IPO Report. 53 SPACs were added in October making the YTD total 169 with a total valuation of ~$57.61 billion.
In this edition of Orrick’s series of life sciences publications, the traditional update on broader venture market financing data is included, depicting the macro-level trends of interest. In addition, given their surge in popularity, SPACs and their particular utility to life sciences businesses are the subject of this edition’s spotlight.